Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07714044 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Rutgers University Study of the Genetics of Blood Cancers

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Recruitment opened Show 4 more changesShow less
    • Start date changed from estimate of Aug 2026 to Sep 22, 2026
    • Eligibility criteria expanded, about 7 words
    • Site details revised
    • Collaborators expanded, about 2 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online and a saliva sample through the mail, sequence DNA, and conduct genetic analyses to identify novel variants and further study known variants associated with leukemia, lymphoma, myeloma and other blood cancers.
Trial Details
NCT Number NCT07714044
Lead Sponsor Rutgers, The State University of New Jersey
Collaborators: Regeneron Pharmaceuticals
Conditions
(from sponsor)		 Blood Cancers, Blood Cancer, Leukemia, Lymphoma, Myeloma, Hematologic Cancer, Hematologic Malignancies, Hematologic Neoplasm +1 more
Related terms Hematologic Neoplasms, Leukemia, Lymphoma, Neoplasms, Plasma Cell
Enrollment 10,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov